Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy

Patent metadata

Field	Value
Publication number	US-11400115-B2
Application number	US-201515305337-A
Country	US
Kind code	B2
Filing date	Apr 23, 2015
Priority date	Apr 23, 2014
Publication date	Aug 2, 2022
Grant date	Aug 2, 2022

Abstract

The present disclosure relates in some aspects to methods, cells, and compositions for preparing cells and compositions for genetic engineering and cell therapy. Provided in some embodiments are streamlined cell preparation methods, e.g., for isolation, processing, incubation, and genetic engineering of cells and populations of cells. Also provided are cells and compositions produced by the methods and methods of their use. The cells can include immune cells, such as T cells, and generally include a plurality of isolated T cell populations or types. In some aspects, the methods are capable of preparing of a plurality of different cell populations for adoptive therapy using fewer steps and/or resources and/or reduced handling compared with other methods.

First claim

What is claimed:

1. A method for producing genetically engineered T cells, the method comprising:
(a) performing a first selection in a closed system, said first selection comprising enriching for one of (i) CD4 + cells and (ii) CD8+ cells from a sample containing primary human T cells, the enrichment thereby generating a first selected population and a non-selected population, wherein the sample is a blood or blood-derived sample from a subject with cancer and comprises at least 1×10 8 cells;
(b) performing a second selection in the closed system, said second selection comprising enriching for the other of (i) CD4+ cells and (ii) CD8+ cells from the non-selected population, the enrichment thereby generating a second selected population,
(c) combining the cells of the first selected population and cells of the second selected population at a ratio of CD4+ cells to CD8+ cells of between 2:1 and 1:2 to produce a culture-initiating composition;
(d) incubating the culture-initiating composition, comprising cells of the first selected population and cells of the second selected population in a culture vessel under stimulating conditions, thereby generating stimulated cells;
(e) introducing a genetically engineered antigen receptor into a plurality of the stimulated cells generated in (d), wherein the antigen receptor binds to an antigen expressed by cells of the cancer; and
(f) incubating the genetically engineered cells generated in (e) to allow for expansion,
wherein the method generates an output composition comprising CD4+ T cells and CD8+ T cells expressing the genetically engineered antigen receptor, and the output composition has a ratio of CD4+ cells to CD8+ cells that is between 5:1 and 1:5.

2. The method of claim 1 , wherein said combining is performed in the closed system.

3. The method of claim 1 , wherein the sample is obtained from a human subject, and the ratio of CD4+ cells to CD8+ cells in the culture-initiating composition is at least 10%, greater or at least 10% less than the ratio of CD4+ cells to CD8+ cells in the sample.

4. The method of claim 1 , wherein the enriching cells in the first selection and the second selection comprises immunoaffinity-based selection.

5. The method of claim 4 , wherein the first immunoaffinity-based selection and the second immunoaffinity-based selection comprise:
contacting cells with an antibody capable of specifically binding to a cell surface marker; and
recovering cells bound to the antibody, thereby effecting positive selection, or recovering cells not bound to the antibody, thereby effecting negative selection, wherein the recovered cells are enriched for the CD4+ cells or the CD8+ cells.

6. The method of claim 1 , wherein the first selection and the second selection are carried out in separate separation vessels, which are operably connected.

7. The method of claim 4 , wherein the immunoaffinity-based selection in the first selection and the immunoaffinity-based selection in the second selection independently each comprises:
contacting cells with an antibody immobilized on or attached to an affinity chromatography matrix, said antibody capable of specifically binding to a cell surface marker to effect positive or negative selection of CD4+ cells or CD8+ cells; and
recovering cells from the affinity chromatography matrix enriched for the CD4+ cells or the CD8+ cells.

8. The method of claim 7 , wherein:
the antibody comprises one or more binding partners capable of forming a reversible bond with a binding reagent immobilized on the affinity chromatography matrix, wherein the antibody is reversibly bound to said matrix during said contacting; and
cells expressing a cell surface marker specifically bound by the antibody on said affinity chromatography matrix are capable of being recovered from the affinity chromatography matrix by disrupting the reversible binding between the binding reagent and binding partner.

9. The method of claim 8 , wherein:
the binding partner is selected from the group consisting of biotin, a biotin analog, and a peptide capable of binding to the binding reagent; and
the binding reagent is selected from among the group consisting of streptavidin, a streptavidin mutein that binds biotin or a streptavidin binding peptide, avidin, and an avidin mutein that binds biotin or a streptavidin binding peptide.

10. The method of claim 8 , wherein disrupting the reversible binding comprises applying a competition reagent to disrupt the bond between the one or more binding partners and the binding reagent, thereby recovering the selected cells from the matrix.

11. The method of claim 7 , wherein the affinity chromatography matrix of the first selection and the affinity chromatography matrix of the second selection are packed in a separation vessel, which is a column.

12. The method of claim 7 , wherein the affinity chromatography matrix adsorbs and/or is capable of selecting at least or at least about 50×10 6 cells/mL.

13. The method of claim 1 , wherein the enriching for the CD4+ cells comprises positive selection based on surface expression of CD4 and the enriching for the CD8+ cells comprises positive selection based on surface expression of CD8.

14. The method of claim 1 , wherein the one of the first selection and the second selection that comprises enriching for the CD8+ cells further comprises enriching for central memory T (T CM ) cells.

15. The method of claim 1 , wherein the ratio of CD4+ cells to CD8+ cells in the culture-initiating composition produced by step (c) is different than the ratio of CD4+ cells to CD8+ cells in the sample.

16. The method of claim 5 , wherein the antibody is immobilized on the outside surface of a bead or a particle.

17. The method of claim 16 , wherein:
the antibody comprises one or more binding partners capable of forming a reversible bond with a binding reagent immobilized on the surface, whereby the antibody is reversibly immobilized to said surface; and
the method comprises after contacting the cells in the sample to the antibody of the first immunoaffinity based selection and the second immunoaffinity based selection, applying a competition reagent to disrupt the bond between the binding partner and binding reagent, thereby recovering the selected cells bound to the antibody.

18. The method of claim 17 , wherein:
the binding partner is selected from among the group consisting of biotin, a biotin analog, and a peptide capable of binding to the binding reagent; and
the binding reagent is selected from among the group consisting of streptavidin, a streptavidin mutein that binds biotin or a streptavidin binding peptide, avidin, and an avidin mutein that binds biotin or a streptavidin binding peptide.

19. The method of claim 1 , wherein the output composition comprises a ratio of CD4+ cells to CD8+ cells that is between 3:1 and 1:3.

20. The method of claim 1 , wherein the stimulating conditions in (d) comprise the presence of an anti-CD3 antibody and an anti-CD28 antibody.

21. The method of claim 1 , wherein the stimulating conditions in (d) comprise an agent capable of activating one or more intracellular signaling domains of one or more components of a TCR complex.

22. The method of claim 1 , wherein:
the genetically engineered antigen receptor comprises a T cell receptor (TCR) or a functional non-TCR antigen receptor; or
the genetically engineered antigen receptor comprises a chimeric antigen receptor (CAR).

23. The method of

Assignees

• Juno Therapeutics Inc

Inventors

• Ramsborg Chris
• Bonyhadi Mark L
• Chan Calvin
• Beauchesne Pascal

Classifications

• C12N2510/00

  Genetically modified cells · CPC title

• B01D15/3804

  Affinity chromatography · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K40/4211

  CD19 or B4 · CPC title